CIPHER PHARMACEUTICALS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.48 CAD | -3.58% |
|
-8.87% | +53.07% |
| Mar. 15 | Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024 | |
| Mar. 14 | Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023. | CI |
| Sales 2024 * | 28.87M 20.96M | Sales 2025 * | 29.33M 21.3M | Capitalization | 212M 154M |
|---|---|---|---|---|---|
| Net income 2024 * | 12M 8.71M | Net income 2025 * | 13M 9.44M | EV / Sales 2024 * | 7.34 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.23 x |
| P/E ratio 2024 * |
17.9
x | P/E ratio 2025 * |
20.3
x | Employees | 5 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cipher Pharmaceuticals Inc.
More press releases
| 1 day | -0.28% | ||
| 1 week | -3.14% | ||
| Current month | -1.18% | ||
| 1 month | +4.95% | ||
| 3 months | +55.94% | ||
| 6 months | +95.88% | ||
| Current year | +58.75% |
1 week
8.50
9.55
1 month
7.909.98
Current year
5.529.98
1 year
3.119.98
3 years
1.209.98
5 years
0.389.98
10 years
0.3819.52
| Managers | Title | Age | Since |
|---|---|---|---|
Craig Mull
CEO | Chief Executive Officer | - | 19-03-25 |
Bryan Jacobs
DFI | Director of Finance/CFO | - | 22-08-14 |
James Bowen
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Harold Wolkin
BRD | Director/Board Member | 72 | 16-08-07 |
Douglas N. Deeth
BRD | Director/Board Member | 76 | 23-06-20 |
Craig Mull
CEO | Chief Executive Officer | - | 19-03-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 8.48 | -3.58% | 21 808 |
| 24-04-18 | 8.795 | -0.28% | 30,931 |
| 24-04-17 | 8.82 | -1.01% | 6,227 |
| 24-04-16 | 8.91 | -4.40% | 19,017 |
| 24-04-15 | 9.32 | +0.16% | 68,130 |
Delayed Quote Toronto S.E., April 18, 2024 at 03:59 pm EDT
More quotes
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.795
CAD
Average target price
7.617
CAD
Spread / Average Target
-13.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +58.75% | 154M | |
| +27.97% | 672B | |
| +23.49% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.19% | 211B | |
| -0.53% | 203B | |
| -9.98% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- CPH Stock
